"SomnoMed has received approval to begin the commercialisation of the world’s first oral device for Obstructive Sleep Apnea (OSA) with the ability to objectively measure compliance rates and report back to the clinicians. This is a very important step for the efficacy of COAT ™ devices to clinicians/insurers and we believe this ability will act as a door opener to the prescribers and payers alike for mild to moderate sleep apnea. We upgrade our price target to A$3.23 and retain an Add recommendation. "
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)